Advanced Non Small Cell Lung Cancer Nsclc clinical trials

Explore recruiting advanced non small cell lung cancer nsclc clinical trials.

Recruiting advanced non small cell lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Non Small Cell Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Poland, Spain, Portugal, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression

France, Spain, Hungary, Austria, Italy, Belgium +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

France, Netherlands, Belgium, Germany, Spain, Portugal +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Bulgaria, Hungary, Poland, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) followed by Radical Radiotherapy or Chemoradiotherapy – IDEAR

Portugal

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Advanced Non Small Cell Lung Cancer Nsclc trials by city

Advanced Non Small Cell Lung Cancer Nsclc in Toronto Advanced Non Small Cell Lung Cancer Nsclc in Vancouver Advanced Non Small Cell Lung Cancer Nsclc in Montreal Advanced Non Small Cell Lung Cancer Nsclc in Calgary Advanced Non Small Cell Lung Cancer Nsclc in Edmonton Advanced Non Small Cell Lung Cancer Nsclc in Ottawa Advanced Non Small Cell Lung Cancer Nsclc in Winnipeg Advanced Non Small Cell Lung Cancer Nsclc in Quebec City Advanced Non Small Cell Lung Cancer Nsclc in Hamilton Advanced Non Small Cell Lung Cancer Nsclc in Kitchener Advanced Non Small Cell Lung Cancer Nsclc in London Advanced Non Small Cell Lung Cancer Nsclc in Halifax Advanced Non Small Cell Lung Cancer Nsclc in New York Advanced Non Small Cell Lung Cancer Nsclc in Los Angeles Advanced Non Small Cell Lung Cancer Nsclc in Chicago Advanced Non Small Cell Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease